LORETO
VIDAUR TELLO
Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (23)
2024
-
Author Correction: Lung microbiome on admission in critically ill patients with acute bacterial and viral pneumonia (Scientific Reports, (2023), 13, 1, (17724), 10.1038/s41598-023-45007-4)
Scientific Reports
-
Impact of antimicrobial stewardship in organisms causing nosocomial infection among COVID-19 critically ill adults
European Journal of Internal Medicine, Vol. 119, pp. 93-98
2023
-
Lung microbiome on admission in critically ill patients with acute bacterial and viral pneumonia
Scientific Reports, Vol. 13, Núm. 1
2022
-
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 21
2021
-
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Science immunology, Vol. 6, Núm. 62
-
Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia
ERJ Open Research, Vol. 7, Núm. 1
2019
-
Factors associated with ventilator-associated events: an international multicenter prospective cohort study
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 38, Núm. 9, pp. 1693-1699
-
Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis
Annals of Intensive Care, Vol. 9, Núm. 1
2018
-
Assessing predictive accuracy for outcomes of ventilator-associated events in an international cohort: the EUVAE study
Intensive Care Medicine, Vol. 44, Núm. 8, pp. 1212-1220
-
Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
Intensive Care Medicine, Vol. 44, Núm. 9, pp. 1470-1482
2017
-
Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case–control study
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 1, pp. 123-130
2016
-
Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
Critical Care, Vol. 20, Núm. 1
-
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 1, pp. 196-207
-
Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
Journal of Infection, Vol. 72, Núm. 2, pp. 143-151
2014
-
DALI: Defining antibiotic levels in intensive care unit patients: Are current ß-lactam antibiotic doses sufficient for critically ill patients?
Clinical Infectious Diseases, Vol. 58, Núm. 8, pp. 1072-1083
-
Decrease in Mortality in severe community-acquired pneumococcal pneumonia: Impact of improving antibiotic strategies (2000-2013)
Chest, Vol. 146, Núm. 1, pp. 22-31
2013
-
Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapy
Medicina Intensiva, Vol. 37, Núm. 5, pp. 320-326
-
Early non-invasive ventilation treatment for severe influenza pneumonia
Clinical Microbiology and Infection, Vol. 19, Núm. 3, pp. 249-256
2012
-
Corticosteroid therapy in patients with primary viralpneumonia due to pandemic (H1N1) 2009influenza
Journal of Infection, Vol. 64, Núm. 3, pp. 311-318
-
Elevation of creatine kinase is associated with worse outcomes in 2009 pH1N1 influenza A infection
Intensive Care Medicine, Vol. 38, Núm. 7, pp. 1152-1161